Dana-Farber’s Breast Oncology Center· @DFCI_BreastOnc · X·· 17 小时前评分70
正文 · 原文
Dr. Erica Mayer (@elmayermd) at the #ESMO26 HR+ breast cancer poster session showcasing a recent expert consensus on the management of ribociclib-associated liver-related adverse events in HR+/HER2− #BreastCancer.
59 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：Dana-Farber’s Breast Oncology Center · x.com